Literature DB >> 25553475

Epigenetic programming contributes to development of drug resistance in hematological malignancies.

Qing-yuan Wang1, Hua Zhong1.   

Abstract

Epigenetics is the study of long term and stable but not necessarily heritable alterations in transcriptional potential and gene expression profile of a cell that are not due to any alterations in the DNA sequence. Epigenetic modifications include DNA methylation, posttranslational modifications of histone proteins and expression of small regulatory RNAs. In recent years, the role of epigenetic modifications in the development of hematological malignancies and drug resistance has been studied in depth and has shed light on this important issue. Here, we review the major epigenetic mechanisms that contribute to the generation and evolution of hematological malignancies and development of resistance to chemotherapy.  We will also discuss the development of epigenetic drugs that can overcome resistance to conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25553475     DOI: 10.2741/4333

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  2 in total

1.  The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.

Authors:  Amanda C Sharko; Chang-Uk Lim; Martina S J McDermott; Chuck Hennes; Kingsavanh P Philavong; Tiffanie Aiken; Victor V Tatarskiy; Igor B Roninson; Eugenia V Broude
Journal:  Cells       Date:  2021-01-12       Impact factor: 6.600

2.  DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

Authors:  Simon Peter Gampenrieder; Gabriel Rinnerthaler; Hubert Hackl; Walter Pulverer; Andreas Weinhaeusel; Suzana Ilic; Clemens Hufnagl; Cornelia Hauser-Kronberger; Alexander Egle; Angela Risch; Richard Greil
Journal:  Theranostics       Date:  2018-03-11       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.